Not Just a Woman’s Job: Why Male Contraception Matters

Why is it that when we talk about birth control, we almost always mean women’s birth control?

For decades, birth control has been hailed as one of the greatest advancements in women’s rights, giving them the chance to choose, plan, and control their futures. Although liberatory, this progress has not come without a cost, one that is disproportionately tied to gender. From the pill to IUDs, implants to injections, women have borne the physical, emotional, and financial burden of pregnancy. Meanwhile, male contraceptives remain limited to condoms and vasectomies – leaving the responsibility of birth control largely one-sided.

Hormonal contraceptives used by women function by manipulating the endocrine system to prevent pregnancy. They disrupt ovulation, affect the uterus lining, and thicken cervical mucus to prevent fertilization. These come with a variety of side effects that can significantly impact women’s health and wellbeing: Nausea, headaches, mood swings, breast tenderness, and irregular bleeding are common, particularly in the early months of use. Some also report bloating, weight fluctuations, and a noticeable decrease in libido; side effects that, while often dismissed, can have a real impact on quality of life. Hormonal contraceptives have been associated with a higher risk of blood clots, deep vein thrombosis (DVT), stroke, and heart attack. Prolonged use has also been linked to metabolic imbalances that affect insulin sensitivity and cholesterol levels, while recent research suggests a potential connection to increased risks of depression and anxiety. Additionally, studies indicate a slight increase in the likelihood of breast and cervical cancer, further complicating the already difficult decisions women must navigate when it comes to choosing birth control. 

Meanwhile, intrauterine devices (IUDs), whether hormonal or copper-based, present their own set of challenges: painful insertion, irregular bleeding, and, in rare cases, uterine perforation. Even non-hormonal options like diaphragms and spermicides pose difficulties like reduced efficacy and an increased risk of infections.

While birth control has given women more control over their reproductive choices, it often comes with side effects, health risks, and ongoing costs that many have no choice but to manage. With few male contraceptive options available, the responsibility has remained largely one-sided, contributing to the physical and emotional toll on women. Expanding male contraceptive choices wouldn’t just provide men with more options, it would help ease the burden on women and create a more balanced approach to family planning. New advancements in male contraceptives are opening the door for real change.

Researchers at Monash University in Australia have developed a promising non-hormonal male contraceptive targeting sperm transport. This method inhibits the α1A-adrenergic receptor and the P2X1-purinergic receptor, which are essential for sperm movement, preventing sperm from reaching the egg without disrupting hormonal balance. Preclinical studies have demonstrated its effectiveness and reversibility in animal models, holding promise for future human use.​ 

Another innovative approach comes from NEXT Life Sciences, a Los Angeles-based startup developing Plan A, a long-term, reversible male contraceptive. This method involves a minimally invasive hydrogel injection into the vas deferens, the tube that carries sperm, forming a semi-solid barrier that blocks sperm while allowing other fluids to pass. Designed to last up to ten years, the procedure can be reversed at any time with a second injection that dissolves the gel, restoring fertility. 

Research into male contraceptives has often been stalled due to concerns over side effects like mood swings and libido changes—effects that women have long endured with hormonal birth control. This double standard has slowed progress, leaving women to bear the physical, emotional, and financial burden of pregnancy prevention. The imbalance also affects relationships, where decisions about birth control disproportionately fall on women, sometimes creating tensions when side effects become intolerable. Pharmaceutical companies, driven by market demand, have prioritised female contraception under the assumption that women have more incentive to prevent pregnancy.

Meanwhile, cultural and psychological barriers, such as misconceptions about male fertility, masculinity, and control, have further hindered the adoption of male contraceptives. Expanding options for men would not only reduce the burden on women but also foster a more balanced approach to reproductive responsibility. With advancements in male contraceptives, there is a growing opportunity to redefine contraception as a shared responsibility. However, achieving real progress requires more than just scientific breakthroughs: it requires shifts in policy, healthcare priorities, and societal attitudes. The real question isn’t whether contraception should be a shared responsibility, but why it has taken so long to make that a reality.

Photo Credits: Lorie Shaull/Flickr